Ivacaftor partially corrects airway inflammation in a humanized G551D rat
- 7 April 2021
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 320 (6) , L1093-L1100
Abstract
Animal models have been highly informative for understanding the pathogenesis and progression of cystic fibrosis (CF) lung disease. In particular, the CF rat models recently developed have addressed mechanistic causes of the airway mucus defect characteristic of CF, and how these may change when cystic fibrosis transmembrane conductance regulator (CFTR) activity is restored using new modulator therapies. We hypothesized that inflammatory changes to the airway would develop spontaneously and progressively, and that these changes would be resolved with modulator therapy. To test this, we used a humanized-CFTR rat expressing the G551D variant that responds to the CFTR modulator ivacaftor. Markers typically found in the CF lung were assessed, including neutrophil influx, small airway histopathology, and inflammatory cytokine concentration. Young hG551D rats did not express inflammatory cytokines at baseline but did upregulate these in response to inflammatory trigger. As the hG551D rats aged, histopathology worsened, accompanied by neutrophil influx into the airway and increasing concentrations of TNF-α, IL-1α, and IL-6 in the airways. Ivacaftor administration reduced concentrations of these cytokines when administered to the rats at baseline but was less effective in the rats that had also received inflammatory stimulus. Therefore, we conclude that administration of ivacaftor resulted in an incomplete resolution of inflammation when rats received an external trigger, suggesting that CFTR activation may not be enough to resolve inflammation in the lungs of patients with CF.Keywords
Funding Information
- Cystic Fibrosis Foundation (BIRKET18I0)
- Cystic Fibrosis Foundation (BIRKET20G0)
- Cystic Fibrosis Foundation (ROWE19R0)
- HHS | NIH | National Heart, Lung, and Blood Institute (K08HL131867)
This publication has 36 references indexed in Scilit:
- The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosisEuropean Respiratory Journal, 2019
- Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosisScience Translational Medicine, 2019
- Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage functionScientific Reports, 2018
- Cystic Fibrosis Lung Immunity: The Role of the MacrophageJournal of Innate Immunity, 2016
- Ivacaftor-Induced Proteomic Changes Suggest Monocyte Defects May Contribute to the Pathogenesis of Cystic FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2016
- Origins of Cystic Fibrosis Lung DiseaseNew England Journal of Medicine, 2015
- Bronchiectasis in Infants and Preschool Children Diagnosed with Cystic Fibrosis after Newborn ScreeningThe Journal of Pediatrics, 2009
- Cystic FibrosisNew England Journal of Medicine, 2005
- State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?Respiratory Research, 2003
- Inflammatory Response in Airway Epithelial Cells Isolated from Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2002